a b s t r a c t DACT2, a tumor suppressor gene in various tumors, is frequently down-regulated via hypermethylation. We found DACT2 gene expressions were dramatically silenced (P = 0.002, n = 8) in our clinical colorectal cancer (CRC) tissues, and TCGA data revealed DACT2 hypermethylation correlated to CRC poor prognosis (P = 0.0129, HR = 0.2153, n = 248). Thus, by screening twelve nutritional compounds, we aimed to find out an effective DACT2 epigenetic stimulator to determine whether DACT2 epigenetic restoration could reverse CRC tumorigenesis. We found that kaempferol significantly increased DACT2 expressions up to 3.47-fold in three CRC cells (HCT116, HT29, and YB5). Furthermore, kaempferol remarkably decreased DACT2 methylation (range: 19.58%-67.00%, P < 0.01), while increased unmethylated DACT2 by 13.72-fold (P < 0.01) via directly binding to DNA methyltransferases DNMT1. By epigenetic reactivating DACT2 transcription, kaempferol notably inhibited nuclear ␤-catenin expression to inactivate Wnt/␤-catenin pathway, which consequently restricted CRC cells proliferation and migration. Moreover, in AOM/DSSinduced CRC tumorigenesis, kaempferol-demethylated DACT2 effectively decreased tumor load (range: 50.00%-73.52%, P < 0.05). By determining the chemopreventive and chemotherapeutic efficacy of a novel DACT2 demethylating stimulator, we demonstrated that DACT2 epigenetic restoration could successfully slow down and reverse CRC tumorigenesis.
Introduction
Colorectal cancer (CRC), a commonly diagnosed malignancy worldwide, leads the third incidence and mortality in the United States [1] . Approximately 15%-20% of CRCs could be subclassified as CpG island methylated phenotype according to the aberrant methylated CpG dinucleotides status. Emerging evidence suggested that aberrant epigenetic alterations are complementary driving factors in CRC pathogenesis [2, 3] . During CRC progres-sion, whole genome screening revealed approximately 92 ∼ 97% of epigenetic and genetic altered genes can be clustered into Wnt/␤-catenin pathway [4] . Dishevelled binding antagonist of beta catenin 2 (DACT2), a negative regulator in Wnt/␤-catenin pathway, is frequently silenced by DNA hypermethylation in esophageal squamous cell carcinoma [5] , breast cancer [6] , and hepatocellular carcinoma [7] . As a tumor suppressor gene, DACT2 suppressed tumor growth, invasion, and metastasis by directly binding with ␤-catenin to hampered the ␤-catenin/LEF1 complex formation in nucleus [8] . Previous study demonstrated that DACT2 was exclusively methylated in 43.3% of CRC tissues, while hypomethylated in normal tissues [8] . However, whether the methylation status of DACT2 can become a prognostic biomarker for CRC and whether its corresponding drug interventions can reverse or prevent CRC tumorigenesis remains unclear.
DNA hypermethylation, mediated by DNA methyltransferases (DNMTs), could inactivate transcriptions of vital tumor suppressor genes, such as APC, MGMT, and SFRP [9, 10] . Thioguanine and 5-azacytidine (5-aza), DNMTs inhibitors, are first-line chemotherapeutic agents for acute myelogenous leukemia. But unfortunately, side effects including phototoxicity, liver injury, and gastrointesti- nal toxicity, were observed after 5-aza and thioguanine long-term exposure [11, 12] . By contrast, overwhelming evidence implied that by dynamically modifying the epigenetic landscape, phytochemical nutritions such as phenols and flavonoids, exert more efficacy with negligible toxicity in cancer prevention [13, 14] . Kaempferol, a nutritional flavonoid widely distributed in various plants [15] , has high effectiveness on anti-diabetes and anti-asthma with tolerable toxicity [16] . Our recent pharmacokinetics analysis revealed kaempferol was mainly accumulated in the colon [17] . But whether kaempferol could reverse CRC progression by modifying epigenetic landscape of DACT2 remains unclear.
By screening twelve nutritional compounds, we found that kaempferol, an effective DACT2 epigenetic stimulator, could significantly demethylate DACT2 by targeting DNMT1 and DNMT3b. Furthermore, using this novel DACT2 demethylating stimulator, we determined whether DACT2 restoration can become a prognostic biomarker for CRC and whether its epigenetic interventions can reverse CRC tumorigenesis. Our results revealed that kaempferol-stimulated DACT2 demethylation remarkably suppressed Wnt/␤-catenin pathway, ultimately prevented CRC tumorigenesis in vivo, and suppressed tumor cell proliferation and metastasis in vitro. The dual effects of DACT2 epigenetic stimulator on CRC treatment indicated DACT2 demethylation could serve as a novel target for drug intervention, and also a potential prognosis biomarker for CRC progression.
Materials and methods

Reagents and antibodies
Kaempferol, 5-aza, trichostatin A (TSA), azoxymethane (AOM), and MTS were purchased from Sigma-Aldrich (St. Louis, MO, USA). Curcumin, honokiol, magnolol, berberine, wogonin, calycosin, artemisinin, dihydroartemisinin, artesunate, astragaloside IV, and formononetin were purchased from Chengdu Must Biotechnology Co.,Ltd. (Chengdu, China). Dextran sulfate sodium (DSS) was purchased from MP Biomedicals (Santa Ana, CA, USA). All the antibodies used in this study were obtained from Cell Signaling Technology (Boston, MA, USA).
Cell culture
HCT116 and HT29 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA), and cultured in DMEM with 10% FBS. YB5 cells, donated by Dr. Jean-Pierre Issa, are generated from human colorectal adenocarcinoma SW48 transfected with hypermethylated CMV/GFP. GFP could be reactivated when YB5 promoter undergo demethylation and H3K9 acetylation, which is served as a signal for determining the effectiveness of potential demethylating agents [18] . YB5 cells were selected with G418, and routinely maintained in RPMI-1640 medium with 10% FBS.
Clinical specimens
All clinical specimens enrolled in this research were collected from Nanfang Hospital with approval of Medical Ethics Committee of Nanfang Hospital, and classificated as CRC by colonoscopy and H&E staining (Supplement Table 1 ). The informed written consent was obtained in accordance with the Declaration of Helsinki. TNM staging was made according to American Joint Committee on Cancer (AJCC, 7th edition).
Cell viability assay
HCT116, HT29, and YB5 cells were seeded into 96-well plates with 1 × 10 4 cells/well overnight, then treated with kaempferol (1.25-150 M) for 72 h. MTS assay was performed to evaluate the cell viability.
RNA extraction, cDNA synthesis, quantitative real-time PCR
Using scientific geneJET genomic RNA purification kit (Thermo Fisher, MA, USA), total mRNA extracted from the kaempferoltreated cells was reversed to cDNA using the SuperScript III first-strand synthesis system (Invitrogen, CA, USA). The gene expression levels of DACT2 and target genes in Wnt/␤-catenin signaling pathway were determined by qPCR using the Power SYBR Green PCR master mix (Applied Biosystems, CA, USA) in ABI7900HT system (Applied Biosystems). GAPDH was used as an internal control. The forward and reverse primers used were shown in Supplement Table 2 .
Fluorescence reactivation analysis
YB5 cells were seeded in 35 mm confocal dishes for overnight and then treated with kaempferol (1.25 M, 2.5 M, and 5 M) for 72 h. The combination of 2.5 M 5-aza and 500 nM TSA (only treated for 24 h before harvest) was used as positive control. YB5 cells were fixed with 4% formaldehyde for 5 min, washed with PBS, then stained with PI. Fluorescence intensities of GFP and PI were detected by confocal.
Methylation-specific PCR (MSP)
Genomic DNA was extracted from the kaempferol-treated cells using Genomic DNA purification kit (Thermo, MA, USA). The bisulfite converted DNA was prepared according to instructions of EZ DNA methylation gold kit (Zymo Research, CA, USA), and subjected to MSP. The PCR products were separated by 1% agarose gel electrophoresis, and the bands were semi-quantitated by densitometry using Quantity One (Bio-Rad, CA, USA). The primers of methylated and unmethylated DACT2 recognizing methylation status of CpG island (-114 to +141 bp) were listed in Supplement Table 2 .
Methylated DNA immunoprecipitation-qPCR (MeDIP-qPCR)
Genomic DNA was sheared to 200-500 bps using Bioruptor sonicator (Diagenode Inc., NJ, USA). Isolated methylated DNA by immunoprecipitation with anti-5 -methylcytosine antibody. Then the natural methylation DNA was quantified by qPCR (primers were listed in Supplement Table 2 ). According to the standard curve of the serial dilution of input DNA, the enrichment of methylated DNA was calculated.
Quantitative methylation profiling with MassARRAY system
Bisulfite converted genomic DNA was subjected to T7-promoter tagged PCR amplification (Primers list in Supplement Table 2 ), after in vitro RNA transcription and uracil-specific cleavage by RNase A, MALDI-TOF MS were performed to analyze the cleavage products (methylated and non-methylated template DNA) [19] .
Protein lysate extraction and western blot
The total protein was prepared in RIPA buffer (Sigma-Aldrich St. MO, USA). The concentration of protein was determined by BCA (Pierce, IL, USA). 30 g total protein was loaded on 4%-15% SDS polyacrylamide gel electrophoresis (Bio-Rad, CA, USA) and transferred onto PVDF membranes. The membranes were blocked with 5% BSA for 2 h and then incubated with primary antibodies at 4 • C overnight. After washed with TBST, the membranes were incubated with secondary antibodies. The density of bands was determined by chemiluminescence. ␤-actin, GAPDH were used as internal controls for cytoplasm proteins, while lamin-A was used for nuclear protein loading.
Molecular docking
The docking study was performed by Autodock4.2 software. The 3D structures of DNMT1 (PDB: 3PTA) and DNMT3A (PDB ID: 2QRV) were downloaded from PDB database, ligand was removed via Chimera and prepared in ADT for docking. Kaempferol structure (PUBCHEM CID: 5280863) was converted to 3D coordinates by openBanel2.3. The size of space was set as 70 × 70 × 70 point and other parameter was performed with default of the docking software. Lamarckian genetic algorithm was used for 50 runs. The docking result was viewed by Chimera software.
Cellular thermal shift assay (CETSA)
HCT116 and HT29 cells were lysed using Tissuelyser-24 (Shanghai Jingxin Industrial Development Co., Ltd., Shanghai, China), and cellular supernatants were collected by centrifugation at 14000 rpm for 20 min. Then aliquotted samples into two groups, one treated with kaempferol (5 M) and the other treated with 0.1% DMSO for 30 min. Divided each sample into 5-6 aliquots and heated individually at 37, 40, 43, 46, 49 and 52 • C (optional for DNMT1) for 15 min, then cooled for 3 min. After centrifuged at 14000 rpm for 20 min, the supernatants were separated by SDS-PAGE and analyzed by western blot. The melting curve is fitted by Graphpad with Boltzmann sigmoidal [20] 
Flow cytometry
Kaempferol-treated cells were fixed with 75% ethanol, and permeabilized by 0.1% Triton X-100, then incubated in PBS containing RNase A. HCT116 and HT29 cells were stained with PI for 15 min for cell cycle analysis. For apoptosis analysis, after stained with Annexin V and PI, fluorescence was detected by FACS Aria III flow cytometer (BD Biosciences, Auckland, New Zealand).
Wound healing assay
HCT116 and HT29 cells were planted in 6-well plate to form a confluency monolayer. Cells in the center of the well were scratched and treated with kaempferol, photos were taken at 0 h and 96 h using microscope.
MMPs activity
MMPs activity was detected by Amplite TM universal fluorimetric MMP activity assay kit (AAT Bioquest, CA, USA) followed by standard protocol. [21] . Furthermore, according to growing number of published studies, the tumor incidence of AOM/DSS model in C57BL/6 stain was estimated up to 100%, suggesting C57BL/6 would be the most sensitive mouse stain for AOM/DSS-induced tumorigenesis [22] [23] [24] [25] .
Mice were randomly subjected to AOM injection (10 mg/kg, i.p) as previous [26] , then divided into 3 groups: (a) AOM/DSS (n = 15); (b) AOM/DSS + 75 mg/kg kaempferol (n = 15); (c) AOM/DSS + 150 mg/kg kaempferol (n = 15). Mice were gavaged with 75 and 150 mg/kg kaempferol daily from the 5th to the 25th week. On the 6th week, mice were given 1.5% DSS (w/v) for 1 week, after that replaced DSS with water for constitutive 14 days. Repeat DSS cycle three times with two weeks intermission for each cycle. Disease activity index (DAI), a therapeutic indicator for colorectal inflammation and tumor incidence, was examined during each DSS exposure as previously [27] . At the endpoint, all mice were sacrificed, and colon length, tumor number, tumor size and organ indexes were also evaluated with microscope and epithelial colon cells were collected.
Histological analysis and immunofluorescence
Fixed colon tissues collected from AOM/DSS-induced CRC mice were embedded in paraffin, and sliced into 4 m, then stained with H&E. Immunofluorescence staining against PCNA and ␤-catenin was performed according to our previous study [28] .
Survival and methylation analysis
RNA-seq and HumanMethylation450 microarray data (TCGA, provision) were downloaded (619 in total). RSEM normalized value and beta-values of methylation were obtained. Pearson coefficient was performed to calculate the correlation between DACT2 gene expression and methylation (n = 619). For survival analysis, DACT2 hypomethylation and hypermethylation groups were defined with threshold (beta value < 0.2 as hypomethylation, while beta value > 0.8 as hypermethylation; only 248 patients were left based on these threshold). Then the overall survival was analyzed by Cox regression analysis, and Kaplan-Meier curve was plotted by Graphpad 5.0.
Statistical analysis
All data were presented as mean ± standard derivation (SD). One-way ANOVA with or without Tukey-Kramer multiple comparison (post hoc) tests were used to evaluate statistical differences. Differences were considered significant when p-values < 0.05.
Results
DACT2 hypermethylation correlated CRC poor prognosis, and suppressed DACT2 gene transcription
To determine the role of DACT2 in CRC development, DACT2 methylation status and gene expression were analyzed in TCGA cohort and clinical samples, respectively. According to KaplanMeier analysis of TCGA cohort, CRC patients with DACT2 hypermethylation had poor overall survival rates compared to that of patients harbored hypomethylated DACT2 (n = 248, P = 0.0129, HR = 0.2153, Fig. 1A ). And DACT2 methylation was negatively correlated to its gene expressions (r = −0.424, P < 0.001, Fig. 1B) , suggesting DNA hypermethylation directly attributed to DACT2 transcriptional inactivation. To evaluate the basal gene expressions of DACT2 in CRC tissues, eight paired clinical specimens (tumor and corresponding adjacent normal tissues) were collected from CRC patients (Supplement Table 1 ). Compared with the adjacent normal tissues, DACT2 gene expressions were extremely down-regulated in tumor tissues (Fig. 1C, P < 0.05) . And the overall DACT2 expres- The correlation between DACT2 gene expression (log RSEM) and methylation using TCGA cohort (n = 619). (C) DACT2 mRNA levels in paired clinical specimens (n = 8), including tumor and corresponding adjacent normal tissues. All the clinical samples were histological classified as CRC in stage II-IV. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with the adjacent normal tissues. All figures were prepared according to the corresponding guidelines [32] .
sions in the adjacent normal tissues is 3.70-fold higher than that in tumor tissues (Fig. 1C , P = 0.002).
DACT2 hypermethylation in CRC cells were significantly reversed by kaemperol through epigenetic modification
Considering DACT2 low expression in CRC tissues, to find out the effective DACT2 stimulator, twelve nutritional compounds were tested. Compared to other candidate compounds, kaempferol significantly elevated DACT2 gene expression both in HT29 and HCT116 cells (SFig. 1, P < 0.001). Furthermore, in three DACT2 down-regulated CRC cells (HCT116, HT29, and YB5, Fig. 2A , P < 0.001), kaempferol dose-dependently increased DACT2 expression ratios (rang: 1.74-fold to 3.47-fold, Fig. 2B , P < 0.01) with no observable toxicity (SFig. 2A).
YB5, GFP-expressing cells with hypermethylated promoter [18] , was used to evaluate the epigenetic modifying effect of kaempferol. We found kaempferol (2.5 M and 5 M) remarkably stimulated GFP fluorescence, suggesting kaempferol directly regulated DNA demethylation (Fig. 2C) . To further evaluate the particular demethylating effect of kaempferol on DACT2 CpG island (−114 to +141 bp), MSP was performed. Compared to 0.1% DMSO, kaempferol dose-dependently increased the unmethylation ratios of DACT2 (unmethylated/methylated) in three CRC cells (Fig. 2D , P < 0.05). To complement MSP, natural methylated DNA without bisulfite conversion was directly immunoprecipitated. As expected, kaempferol contrarily decreased the methylated DACT2 ratios (Fig. 2E , P < 0.01). Specifically, kaempferol notably demethylated DACT2 at CpG islands of 1-8 and 26-28 both in HCT116 and HT29 cells (Fig. 2F and SFig. 2B, P < 0.01). These indicated that kaempferol could serve as an effective DACT2 epigenetic stimulator to activate DACT2 transcription by increasing DNA demethylation.
Kaempferol demethylated DACT2 through targeting DNMT1
To further determine the mechanism of kaempferol-induced DACT2 demethylation, the protein levels of classical epigenetic modifiers (DNMTs and HDACs) were detected. Compared to control, kaempferol dose-dependently suppressed the protein expressions of DNMT1, DNMT3a and DNMT3b in HCT116 and HT29 cells (Fig. 3A) . In agreement with previous study [15] , the expressions of HDACs were also notably decreased by kaempferol (Fig. 3B) . To further explore which DNMTs is specifically responsible for kaempferol-induced DACT2 demethylation, docking and CETSA assay were performed. Kaempferol was predicted to bind with the Phe1145, Gly1222, Gly1223, Pro1224, Pro1225, Cys1226, Gln1227, Leu1265, Glu1266, and Asn1267 residues of DNMT1 catalytic region (1139-1616, binding energy: −7.89; Ki: 1.65 M, Fig. 3C ). These ten resides localized in SAM-dependent MTase C5-type domain, while Phe1145 (1150-1151) was close to a critical site for S-adenosylmethionine binding, suggesting kaempferol might either hinder the binding of SAM with DNMT1 or form non-covalent bonds to trap DNMT1. CETSA results revealed kaempferol notably shifted T m50 of DNMT1 by 2.52 • C and 6.23 • C, whereas no liner affinity • C) for 15 min Tm50 indicated the temperature at which half of proteins are precipitated was calculated. In general, when an affinitive compound tightly bound to a protein, Tm50 will shift to more a stabilized temperature. Thus, Tm50 serves as an indication for the affinity of kaempferol binding to DNMT1 and DNMT3a. Representative DNMT1 and DNMT3a bands are shown on the left panel and the melting curve fitted by Graphpad with Boltzmann sigmoidal are shown on the right. was observed on DNMT3a (Fig. 3D) , the greater thermal stabilization suggested that kaempferol is a strong DNMT1-specific binding ligand.
DACT2 epigenetic restoration inhibited Wnt/ˇ-catenin signaling pathway
DACT2, a vital nucleocytoplasmic shuttling protein, directly binds to ␤-catenin, subsequently suppresses Wnt/␤-catenin pathway [8] . To further verify the function of DACT2 epigenetic restoration induced by kaempferol, Wnt/␤-catenin pathway and downstream targets were analyzed. Kaempferol significantly stimulated the expression of ␤-catenin in cytoplasma while attenuated its expression in nucleus (Fig. 4A and B) . Consequently, kaempferol-induced DACT2 re-expression also notably altered the protein expressions of Wnt/␤-catenin pathway, such as decreasing Wnt5a/b and Dvl3 while contrarily increasing the negative regulator Dvl2 and Naked 2 (Figs. 4C) . Meanwhile, kaempferol-induced DACT2 restoration significantly downregulated the genes expression of CTNNB1, LRP6, AXIN1, and DVL3 (Fig. 4D) . Furthermore, the gene expressions of MET and CCND1, two vital downstream genes transcriptionally activated by ␤-catenin, were subsequently downregulated by kaempferol-induced DACT2 demethylation (Fig. 4E , P < 0.05).
Kaempferol-induced DACT2 re-expression remarkably suppressed CRC cells tumor proliferation and metastasis
Wnt/␤-catenin signaling is the most predominant signaling pathway contributed to tumor initiation, progression and metastasis [29] . To determine the consequent cell fate caused by kaempferol-induced DACT2 demethylation, cell apoptosis, cell cycle, and cell migration were analyzed. As shown in Fig. 5A , kaempferol dose-dependently increased cell apoptosis and necrosis in HCT116 and HT29 cells (Fig. 5A, P < 0.05) . Furthermore, kaempferol-stimulated DACT2 upregulation remarkably arrested HCT116 and HT29 cells at S and G0/G1 phases, respectively (Fig. 5B) . In addition, protein expression of apoptotic-associated caspase-3 was notably increased by kaempferol-induced DACT2 restoration, while anti-apoptotic protein Bcl-2 was contrarily reduced (Fig. 5C , P < 0.05). Wound healing results also indicated that kaempferol dramatically suppressed the migratory capacities of HCT116 and HT29 cells (Fig. 5D , P < 0.01). And MMPs activity was also significantly reduced by DACT epigenetic stimulator kaempferol ( Fig. 5D , P < 0.05).
Kaempferol-induced DACT2 restoration suppressed tumorigenesis in AOM/DSS-induced CRC mice model
To evaluate the effects of kaempferol on DACT2 expression and the subsequent chemoprevention efficacy in vivo, the AOM/DSSinduced CRC model was established [21] (Fig. 6A ). Compared to model, DACT2 gene expressions in tumor tissues were significantly increased by kaempferol (Fig. 6B, P < 0.05) . Consequently, kaempferol-induced DACT2 restoration significantly suppressed ␤-catenin protein expression in CRC tissues (Fig. 6C) , and CTNNB1 and LRP6 gene expressions were also notably suppressed in kaempferol-treated tumor tissues (Fig. 6C , P < 0.01).
Without observable systemic toxicity, kaempferol successfully sustained the body weight against DSS intake (SFig. 3). Furthermore, kaempferol dose-dependently reduced DAI in three cycles of DSS consumption (Fig. 6E , P < 0.05). And the colon length was improved from 6.40 ± 0.42 in the model group to 7.70 ± 0.30 and 8.00 ± 0.46 after kaempferol treatments ( Fig. 6D , P < 0.05). These suggested DACT2 stimulator kaempferol, an effective anti-colitis agent, would be a potential CRC chemopreventive compound. Most importantly, kaempferol significantly suppressed the tumor load by 50.00 ± 1.47% and 73.52 ± 1.05%, respectively. Additionally, kaempferol treatments markedly decreased the tumor nodules (>4 mm) from 39.90 ± 1.89% in model group to 24.44 ± 1.57% and 16.08 ± 0.96%, respectively ( Fig. 6F , P < 0.01). H&E and PCNA staining results revealed that DACT2 stimulator kaempferol notably restricted tumor cell proliferation to form lesser visible tumor loci (Fig. 6G ).
Discussion
In this study, considering the hypermethylation of DACT2 in CRC, we screened twelve nutritional compounds to find out an effective DACT2 epigenetic stimulator. Next, by revealing the chemoprevention and chemotherapeutic effect of this DACT2 stimulator, we aim to lay the foundation for further exploring DACT2 demethylation as novel and feasible strategy for drug discovery, and also provide solid evidence to determine DACT2 methylation status as a promising prognostic biomarker for CRC tumorigenesis. We found that kaempferol, the top DACT2 stimulator among 12 candidate compounds, effectively demethylated DACT2 promoter (CpG island: −114-+ 366 bp) by specifically binding to DNMT1 and inhibiting its nuclear expression. Subsequently, kaempferolinduced DACT2 epigenetic restoration significantly restricted CRC cell proliferation and migration via inactivating Wnt/␤-catenin pathway, which ultimately suppressed and prevented CRC tumorigenesis.
Our findings provide a novel DACT2 demethylating stimulator to verify and expand previously established link between DACT2 and CRC, suggesting DACT2 demethylation is strongly correlated with CRC prognosis. Recent studies revealed that the methylation status of certain genes is closely correlated to not only chemotherapeutic sensitivity but also cancer prognosis. Such as in esophageal cancer, LINE-1 methylation is important for predicting cancer prognosis and monitoring efficacy of adjuvant therapy [30] . But for CRC, the potential epigenetic biomarkers are still lacking and whether their modifications could effectively suppress CRC progression are also unknown. Previous study revealed that DACT2, hypermethylated tumor suppressor gene in CRC, correlated with CRC prognosis in TCGA dataset [8] . In good agreement with previous study, our results also demonstrated that CRC patients with DACT2 hypomethylation may have better prognosis (p = 0.0129, HR = 0.2153, Fig. 1A) , and silenced DACT2 transcription in CRC patients was ascribed to its DNA methylation (Fig. 1B , r = −0.424, P < 0.001). In eight clinical CRC samples and three CRC cells (HCT116, HT29, and YB5), we also found that DACT2 gene expressions were extremely lower than those in the adjacent normal tissues (Fig. 1C and Fig. 2A , P < 0.05). By utilizing DACT2 epigenetic stimulator, we found that Wnt/␤-catenin pathway, the most CRC prognosis-related cellular network [4] , was consequently suppressed (Fig. 4 and SFig. 4), implying DACT2 epigenetic alteration may significantly influence CRC tumorigenesis and prognosis.
Our study shed a light for discovering drug interventions on epigenetic modifiers or hypermethylated genes to exert tumor suppression effectiveness. Even the vital role of DACT2 in CRC is preliminarily investigated, whether DACT2 methylation status can become a CRC prognostic biomarker and whether its corresponding drug interventions can reverse or prevent CRC tumorigenesis remains unclear. We found that kaempferol, without obvious toxicity (SFig. 3A and SFig. 2A), dose-dependently increased DACT2 gene expression both in vivo (Fig. 6B , P < 0.05) and in vitro (Fig. 2B , P < 0.001) via DNMT1-targeted demethylating DACT2 CpG island (-114-+ 366 bp) (Figs. 2-3 and SFig. 2B). Compared to the significant and consistent down-regulated protein expression levels of DNMTs, only the expressions of HDAC1 and phosphorylated HDAC 4, 5, 7 were consistently reduced by kaempferol in a dosedependent manner. Recent study revealed that Dact paralogs conserved, though weak, formed complex with GSK3, HDAC1, and TGF␤ receptors, implying HDAC1 may probably involve in DACT2 functional activation [31] . Meanwhile, UCSC (http://genome.ucsc. edu/) and HHMD (Human Histone Modification Database, http:// 202.97.205.78/hhmd/) also showed that various histone modification sites such as H2A (H2AK9ac, H2AK5ac), H2B (H2BK12ac, H2BK5ac), H3 (H3K9ac, H3K14ac, H3K18ac, H3K36ac, H3K27ac, H3K4ac), and H4 (H4K8ac, H4K16ac) were also involved in DACT2 promoter, indicating histone acethylation would be another alternative epigenetic mechanism responsible for DACT2 transcription. With DACT2 epigenetic restoration, kaempferol successfully prevent CRC tumorigenesis through significantly decreasing tumor load by up to 73.52% in AOM/DSS-induced CRC model (Fig. 6F , P < 0.05). Meanwhile, kaempferol-induced DACT2 demethylation notably induced cell apoptosis (Fig. 5A and 5C , P < 0.05), arrested cell cycle (Fig. 5B , P < 0.05), and inhibited CRC cell migration (Fig. 5D , P < 0.05). DACT2 epigenetic stimulator could exert dual efficacy for (D) Tumor migration was measured by wound healing and MMPs activity assay, respectively. All the data are representative of three individual experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared with 0.1% DMSO treatment. CRC prevention and treatment, implying DACT2 epigenetic restoration could successfully slow down and reverse CRC tumorigenesis.
Conclusions
Our present study advanced our understandings of DACT2 as followings: (i) It revealed the direct correlation among DACT2 hypermethylation, prognosis and transcriptions, which would benefit our further research for investigating DACT2 as a novel epigenetic prognosis biomarker. (ii) By screening twelve nutritional compounds, we determined kaempferol is the strongest DACT2 epigenetic stimulator. Subsequently, kaempferol-suppressed CRC tumorigenesis suggested that DACT2 demethylating activation is a promising strategy for anti-tumor or chemoprevention drug discovering, and also contrarily implied that DACT2 epigenetic alteration is vital for CRC progression. (iii) Our mechanistic study uncovered the vital role of kaempferol as a specific DNMT1-binding ligand to exert DNA demethylating effects, which shed a light on exploring more potential DNMTs-specific affinity compounds to further determine the unique demethylating effects of DNMTs on gene demethylation. The findings we found laid the foundation for employing an effective epigenetic stimulator to further understand the vital role of epigenetic biomarkers or hypermethylated tumor suppressor genes in cancers.
